# Can-Fite BioPharma Ltd.: overview CANF · NYSE · CIK 1536196 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/canf.md) · [Financials](/companies/canf/financials.md) · [Filings](/companies/canf/filings.md) · [Insiders](/companies/canf/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.9](/filings/0001213900-23-024298.md) | [0.8](/filings/0001213900-25-031298.md) | [0.7](/filings/0001213900-26-034447.md) | [0.7](/filings/0001213900-26-034447.md) | [0.4](/filings/0001213900-26-034447.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1505.5%)](/filings/0001213900-24-026947.md) | [(1246.4%)](/filings/0001213900-25-031298.md) | [(1103.0%)](/filings/0001213900-26-034447.md) | [(1206.2%)](/filings/0001213900-26-034447.md) | [(2456.8%)](/filings/0001213900-26-034447.md) | | Net margin | % | [(1478.9%)](/filings/0001213900-24-026947.md) | [(1255.9%)](/filings/0001213900-25-031298.md) | [(1027.5%)](/filings/0001213900-26-034447.md) | [(1169.1%)](/filings/0001213900-26-034447.md) | [(2426.7%)](/filings/0001213900-26-034447.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001213900-24-026947.md) | [(0.01)](/filings/0001213900-25-031298.md) | [(17.92)](/filings/0001213900-26-034447.md) | [(10.86)](/filings/0001213900-26-034447.md) | [(5.97)](/filings/0001213900-26-034447.md) | | Free cash flow | $m | [(9.9)](/filings/0001213900-24-026947.md) | [(10.8)](/filings/0001213900-25-031298.md) | [(8.4)](/filings/0001213900-26-034447.md) | [(7.6)](/filings/0001213900-26-034447.md) | [(9.0)](/filings/0001213900-26-034447.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/canf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $96.6k | 32,533 | | Reduced −1,617 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $51.8k | 17,433 | | Reduced −3,475 | | [FIFTH THIRD BANCORP](/funds/35527.md) | 2026-06-30 | $446 | 150 | | Unchanged | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $175 | 59 | | Reduced −66 | | [Activest Wealth Management](/funds/1883134.md) | 2026-06-30 | $30 | 10 | | Unchanged | | [TD Waterhouse Canada Inc.](/funds/1999606.md) | 2026-06-30 | $4 | 1 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3 | 1 | | Unchanged | | [Avion Wealth](/funds/1792704.md) | 2026-06-30 | $0 | 5 | | Unchanged | ## Recent filings [All 855 filings](/companies/canf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 07:03 ET | [6-K](/filings/0001213900-26-112266.md) | Report of a foreign private issuer, period 2026-10-26 | 0001213900-26-112266 | | 2026-09-09 | 07:02 ET | [6-K](/filings/0001213900-26-098205.md) | Report of a foreign private issuer, period 2026-09-09 | 0001213900-26-098205 | | 2026-09-08 | 08:21 ET | [6-K](/filings/0001213900-26-097856.md) | Report of a foreign private issuer, period 2026-06-30 | 0001213900-26-097856 | | 2026-09-03 | 11:43 ET | [6-K](/filings/0001213900-26-097048.md) | Report of a foreign private issuer, period 2026-09-03 | 0001213900-26-097048 | | 2026-09-02 | 09:06 ET | [6-K](/filings/0001213900-26-096480.md) | Report of a foreign private issuer, period 2026-09-02 | 0001213900-26-096480 | | 2026-09-02 | 07:03 ET | [6-K](/filings/0001213900-26-096442.md) | Report of a foreign private issuer, period 2026-09-02 | 0001213900-26-096442 | | 2026-08-17 | 07:10 ET | [6-K](/filings/0001213900-26-090478.md) | Report of a foreign private issuer, period 2026-08-17 | 0001213900-26-090478 | | 2026-08-12 | 07:03 ET | [6-K](/filings/0001213900-26-088029.md) | Report of a foreign private issuer, period 2026-08-12 | 0001213900-26-088029 | | 2026-08-03 | 07:04 ET | [6-K](/filings/0001213900-26-084244.md) | Report of a foreign private issuer, period 2026-08-03 | 0001213900-26-084244 | | 2026-07-20 | 07:04 ET | [6-K](/filings/0001213900-26-079394.md) | Report of a foreign private issuer, period 2026-07-20 | 0001213900-26-079394 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-034447.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1536196 - Tickers: CANF - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 07:04 ET. No prices; not investment advice.